(Q46083342)

19 December 2017

title

Nonalcoholic fatty liver disease and the renin-angiotensin system blockers in the patients with chronic kidney disease (English)

1 reference

19 December 2017

metabolic dysfunction–associated steatotic liver disease

1 reference

1 reference

Lidija Orlic

1

1 reference

19 December 2017

Ivana Mikolasevic

2

1 reference

19 December 2017

Vesna Lukenda

3

1 reference

19 December 2017

Kata Anic

4

1 reference

19 December 2017

Ita Jelic

5

1 reference

19 December 2017

Sanjin Racki

6

1 reference

19 December 2017

publication date

21 November 2014

1 reference

19 December 2017

published in

Vienna Clinical Weekly

1 reference

19 December 2017

volume

127

1 reference

19 December 2017

issue

9-10

1 reference

19 December 2017

page(s)

355-362

1 reference

19 December 2017

https://scigraph.springernature.com/pub.10.1007/s00508-014-0661-y

exact match

0 references

cites work

The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association

1 reference

https://api.crossref.org/works/10.1007%2FS00508-014-0661-Y

Nonalcoholic fatty liver disease (NAFLD): a new risk factor for adverse cardiovascular events in dialysis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00508-014-0661-Y

Controlled attenuation parameter (CAP): a novel VCTE™ guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00508-014-0661-Y

Transient elastography: Kill two birds with one stone?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00508-014-0661-Y

Relationship between kidney function and liver histology in subjects with nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00508-014-0661-Y

Relationship between non-alcoholic fatty liver disease and kidney function: a communication between two organs that needs further exploration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00508-014-0661-Y

Risk of chronic kidney disease in patients with non-alcoholic fatty liver disease: is there a link?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00508-014-0661-Y

Chronic kidney disease and nonalcoholic Fatty liver disease proven by transient elastography.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00508-014-0661-Y

Hepatic fibrosis and the renin-angiotensin system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00508-014-0661-Y

ACE inhibition and AT1 receptor blockade prevent fatty liver and fibrosis in obese Zucker rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00508-014-0661-Y

Renin-angiotensin system in the pathogenesis of liver fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00508-014-0661-Y

Update on new aspects of the renin-angiotensin system in liver disease: clinical implications and new therapeutic options.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00508-014-0661-Y

Cardiovascular protective role of a low-dose antihypertensive combination in obese Zucker rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00508-014-0661-Y

Liver fibrogenesis: a new role for the renin-angiotensin system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00508-014-0661-Y

Angiotensin receptor blockers in the treatment of NASH/NAFLD: could they be a first-class option?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00508-014-0661-Y

Liver enzymes in patients with chronic kidney disease undergoing peritoneal dialysis and hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00508-014-0661-Y

Updated definitions of healthy ranges for serum alanine aminotransferase levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00508-014-0661-Y

Steatohepatitis: a tale of two "hits"?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00508-014-0661-Y

Systematic review: the diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00508-014-0661-Y

Non-alcoholic fatty liver disease and increased risk of cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00508-014-0661-Y

Reliability of transient elastography for the detection of fibrosis in non-alcoholic fatty liver disease and chronic viral hepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00508-014-0661-Y

Nonalcoholic fatty liver disease: a manifestation of the metabolic syndrome.

21 January 2018

1 reference

12 December 2020

Effect of Telmisartan or Losartan for Treatment of Nonalcoholic Fatty Liver Disease: Fatty Liver Protection Trial by Telmisartan or Losartan Study (FANTASY).

1 reference

12 December 2020

Non-alcoholic fatty liver disease; a part of the metabolic syndrome in the renal transplant recipient and possible cause of an allograft dysfunction

1 reference

12 December 2020

Nonalcoholic fatty liver disease and the renin-angiotensin system: Implications for treatment

1 reference

12 December 2020

Nonalcoholic fatty liver disease and its association with cardiovascular disease.

1 reference

12 December 2020

The pathogenesis of decreased aspartate aminotransferase and alanine aminotransferase activity in the plasma of hemodialysis patients: the role of vitamin B6 deficiency

1 reference

12 December 2020

Local angiotensin II and transforming growth factor-beta1 in renal fibrosis of rats

1 reference

12 December 2020

10.1007/S00508-014-0661-Y

Identifiers

DOI

1 reference

19 December 2017

PubMed ID

25412597

1 reference

19 December 2017